OLB) has raised £4.865 million in gross proceeds following an upsized and oversubscribed share offering, the London-listed biopharmaceutical company said on Friday, providing new capital to advance its clinical pipeline and extend its cash runway into 2027. The company issued 6 million shares at 2.5 pence each through a bookbuild offer that raised £150,000, adding to funds previously secured through a placing and subscription. 